These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8102646)

  • 21. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior.
    Feldman DJ; Frank RA; Kehne JH; Flannery R; Brown D; Soni S; Byrd G; Shah S
    Pharmacol Biochem Behav; 1997 Oct; 58(2):565-72. PubMed ID: 9300620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release.
    Broderick PA; Piercey MF
    J Neural Transm (Vienna); 1998; 105(6-7):749-67. PubMed ID: 9826116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons.
    Sorensen SM; Humphreys TM; Palfreyman MG
    Eur J Pharmacol; 1989 Apr; 163(1):115-8. PubMed ID: 2744086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens.
    Compton DR; Johnson KM
    J Pharmacol Exp Ther; 1989 Feb; 248(2):521-30. PubMed ID: 2918468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons.
    Chiodo LA; Bunney BS
    J Neurosci; 1983 Aug; 3(8):1607-19. PubMed ID: 6135762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Taylor VL; Fadayel GM; Humphreys TM; Nieduzak TR; Sorensen SM
    Eur J Pharmacol; 1992 Sep; 220(2-3):151-9. PubMed ID: 1425989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.
    Schmidt CJ; Fadayel GM
    Eur J Pharmacol; 1995 Feb; 273(3):273-9. PubMed ID: 7737334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
    Akhtar M; Uma Devi P; Ali A; Pillai KK; Vohora D
    Fundam Clin Pharmacol; 2006 Aug; 20(4):373-8. PubMed ID: 16867021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.
    Creed-Carson M; Oraha A; Nobrega JN
    Behav Brain Res; 2011 Jun; 219(2):273-9. PubMed ID: 21262266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
    Cook L; Tam SW; Rohrbach KW
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
    Matsubara R
    Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
    Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
    J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.